CN114728974B - 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 - Google Patents

作为btk抑制剂的吡咯并嘧啶类化合物及其应用 Download PDF

Info

Publication number
CN114728974B
CN114728974B CN202080078768.4A CN202080078768A CN114728974B CN 114728974 B CN114728974 B CN 114728974B CN 202080078768 A CN202080078768 A CN 202080078768A CN 114728974 B CN114728974 B CN 114728974B
Authority
CN
China
Prior art keywords
compound
added
reaction
acid
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080078768.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN114728974A (zh
Inventor
张杨
伍文韬
耿开骏
李秋
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Longchuan Biomedical Technology Co ltd
Original Assignee
Zhejiang Longchuan Biomedical Technology Co ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Longchuan Biomedical Technology Co ltd, Medshine Discovery Inc filed Critical Zhejiang Longchuan Biomedical Technology Co ltd
Priority to CN202311079865.7A priority Critical patent/CN117551103A/zh
Publication of CN114728974A publication Critical patent/CN114728974A/zh
Application granted granted Critical
Publication of CN114728974B publication Critical patent/CN114728974B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080078768.4A 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用 Active CN114728974B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311079865.7A CN117551103A (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201911109773 2019-11-13
CN2019111097732 2019-11-13
CN201911288492 2019-12-13
CN2019112884928 2019-12-13
CN202010096582 2020-02-17
CN2020100965823 2020-02-17
CN2020107112709 2020-07-22
CN202010711270 2020-07-22
PCT/CN2020/128597 WO2021093839A1 (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311079865.7A Division CN117551103A (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Publications (2)

Publication Number Publication Date
CN114728974A CN114728974A (zh) 2022-07-08
CN114728974B true CN114728974B (zh) 2023-09-19

Family

ID=75912541

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080078768.4A Active CN114728974B (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN202311079865.7A Withdrawn CN117551103A (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311079865.7A Withdrawn CN117551103A (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Country Status (6)

Country Link
US (1) US12378253B2 (cg-RX-API-DMAC7.html)
EP (1) EP4059935A4 (cg-RX-API-DMAC7.html)
JP (1) JP7473642B2 (cg-RX-API-DMAC7.html)
KR (1) KR102793446B1 (cg-RX-API-DMAC7.html)
CN (2) CN114728974B (cg-RX-API-DMAC7.html)
WO (1) WO2021093839A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234558A4 (en) * 2020-12-07 2024-10-23 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
JP7645573B2 (ja) * 2021-05-12 2025-03-14 ジャージアン・ロングチャーム・バイオ-テック・ファーマ・カンパニー・リミテッド ピロロピリミジン類化合物の結晶形およびその調製方法
CN117500806A (zh) * 2021-05-28 2024-02-02 默沙东有限责任公司 Btk抑制剂及其中间体的合成
EP4448523A1 (en) 2021-12-14 2024-10-23 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101594871A (zh) * 2006-05-26 2009-12-02 诺瓦提斯公司 吡咯并嘧啶化合物及其用途
EP3042903A1 (en) * 2015-01-06 2016-07-13 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2017111787A1 (en) * 2015-12-23 2017-06-29 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN109890821A (zh) * 2016-08-24 2019-06-14 艾科尔公司 氨基-吡咯并嘧啶酮化合物及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20170311T1 (hr) * 2012-08-06 2017-04-21 Acea Biosciences Inc. Novi spojevi pirolopirimidina kao inhibitori protein kinaza

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101594871A (zh) * 2006-05-26 2009-12-02 诺瓦提斯公司 吡咯并嘧啶化合物及其用途
EP3042903A1 (en) * 2015-01-06 2016-07-13 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
WO2017111787A1 (en) * 2015-12-23 2017-06-29 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
CN109890821A (zh) * 2016-08-24 2019-06-14 艾科尔公司 氨基-吡咯并嘧啶酮化合物及其使用方法

Also Published As

Publication number Publication date
CN114728974A (zh) 2022-07-08
JP2023506691A (ja) 2023-02-20
EP4059935A4 (en) 2024-02-28
KR20220097455A (ko) 2022-07-07
US20230357248A1 (en) 2023-11-09
CN117551103A (zh) 2024-02-13
WO2021093839A1 (zh) 2021-05-20
US12378253B2 (en) 2025-08-05
EP4059935A1 (en) 2022-09-21
KR102793446B1 (ko) 2025-04-09
JP7473642B2 (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
KR102793446B1 (ko) Btk 억제제로서의 피롤로피리미딘 화합물 및 이의 용도
EP3741756B1 (en) Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor
JP7313492B2 (ja) Dna-pk阻害剤としてのキノリン及びシンノリン誘導体
EP3753937B1 (en) Atr inhibitor and application thereof
CN113993860B (zh) 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物
CN117083281A (zh) 嘧啶并杂环类化合物及其应用
CN109790148A (zh) 具有usp30抑制剂活性的氰基取代的杂环
WO2021115401A1 (zh) 具有大环结构的含氟并杂环衍生物及其用途
JP2023526490A (ja) フルオロピロロピリジン系化合物及びその使用
CN114008046A (zh) 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物
WO2020156568A1 (zh) 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物
CN116438175B (zh) 苯并脲环衍生物及其制备方法和应用
CN117561265B (zh) 二甲基取代的噻唑并内酰胺类化合物及其应用
HK40080199A (en) Pyrrolopyrimidine compound as btk inhibitor and use thereof
US20230183230A1 (en) Compounds containing benzosultam
CN117279923A (zh) 六元杂芳并脲环的衍生物及其应用
CN117561266A (zh) 噻唑并内酰胺并螺杂环类化合物及其应用
TWI795129B (zh) 吡啶并嘧啶酮類化合物
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
CN113286594B (zh) 吡啶并嘧啶类化合物在制备治疗鼻咽癌药物中的应用
JP2020523369A (ja) Gls1阻害剤としての化合物
CN118139865A (zh) 吡咯并吡唑螺环化合物
CN116490504A (zh) 吡咯并吡啶类化合物及其应用
WO2023207991A1 (zh) 稠合喹唑啉类化合物及其应用
CN119998273A (zh) 苄氨基喹啉类化合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20220916

Address after: 310018 room 1-1203, Heda Medicine Valley Center, No. 291, Fucheng Road, Xiasha street, Qiantang new area, Hangzhou, Zhejiang

Applicant after: Zhejiang Longchuan Biomedical Technology Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant